|
| Status |
Public on Dec 17, 2019 |
| Title |
Effect of Pirfenidone on NSCLC [A549 1.5 mg/ml Pirf 24hrs] |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Investigating the effect of Pirfenidone on NSCLC cells
Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated the single drug potency of Pirfenidone, an approved drug for the treatment of lung fibrosis which is known to inhibit TGFB1 mRNA. Human A549 and H1975 lung adenocarcinoma cell lines were stimulated for 6h and 25h with 0.75 mg/ml or 1.5 mg/ml Pirfenidone or the respective volume of PBS as vehicle control. Total RNA was extracted and subjected to transcriptome analysis by microarrays.
|
| |
|
| Overall design |
stimulation of A549 cell line with 1.5 mg/ml Pirfenidone or equal volume of PBS and incubation 24h (N=4 each)
|
| |
|
| Contributor(s) |
Marwitz S |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| Submission date |
Sep 05, 2019 |
| Last update date |
Dec 21, 2019 |
| Contact name |
Sebastian Marwitz |
| Organization name |
Research Center Borstel - Leibniz Lung Center
|
| Department |
Pathology
|
| Street address |
Parkallee 3a
|
| City |
Borstel |
| ZIP/Postal code |
23845 |
| Country |
Germany |
| |
|
| Platforms (1) |
| GPL13497 |
Agilent-026652 Whole Human Genome Microarray 4x44K v2 (Probe Name version) |
|
| Samples (8)
|
|
| This SubSeries is part of SuperSeries: |
|
| Relations |
| BioProject |
PRJNA564085 |
Less...
More...